

Index

ABBREVIATED BIOLOGICS LICENSE APPLICATIONS (aBLAs)

- Generally, § 3:3, 3:6 to 3:14
- Better than reference product, consequences, § 3:10
- BPCIA, jurisdiction before submission of aBLA, § 4:1
- Clinical trials, § 3:8
- Demonstrating biosimilarity requirements, § 3:6 to 3:11
- Exclusivity, interchangeable product, § 3:12
- Interchangeability, demonstrating, § 3:11, 3:12
- Labeling requirements for biosimilar and interchangeable biosimilar products, § 3:13
- Manufacturing information, § 3:7
- NDAs to BLAs, conversion, § 3:5
- No patent linkage, § 3:14
- Proving biosimilarity, § 3:9
- Reference product, consequences of comparison, § 3:10
- Worse than reference product, consequences, § 3:10

ANTICIPATION

- Validity, ineligible subject matter, § 4:82

ANTITRUST ACTIONS

- Generally, § 8:1 to 8:6
- Acquisition and enforcement of intellectual property
 - patent thickets, § 8:5
 - sham litigation, § 8:4
 - walker process fraud, § 8:4
- Challenges to patent settlement agreements, § 8:2

ANTITRUST ACTIONS—Cont'd

- Enforcement. Acquisition and enforcement of intellectual property, above
- Exclusionary contracting and rebating strategies, § 8:6
- Filing agreements with government, § 8:3

APPEALS

- Post-grant proceedings, § 5:20

APPLICATION TYPES

- Abbreviated Biologics License Applications (aBLAs), § 3:3
- Biologics License Applications (BLAs), § 3:2
- Drug products not regulated as biological products, § 3:4
- NDAs to BLAs, conversion, § 3:5

APPROVAL

- FDA Approval** (this index)

ATTORNEYS' FEES

- Remedies, enforceability of patent, § 4:96

BIOBETTERS

- Generally, § 3:15

BIOLOGICS LICENSE

APPLICATIONS (BLAs)

- Generally, § 3:2

BIOLOGICS PRICE

COMPETITION AND INNOVATION ACT (BPCIA)

- Generally, § 2:1, 4:1 to 4:98
- Discovery
 - generally, § 4:61 to 4:68
 - confidentiality tiers, § 4:68
 - expedited discovery, § 4:64

BIOLOGICS PRICE

**COMPETITION AND
INNOVATION ACT (BPCIA)
—Cont'd**

Discovery—Cont'd
 manufacturing information,
 § 4:62
 overlapping patents-in-suit,
 § 4:63
 preliminary injunction, § 4:64
 prosecution bars, § 4:66
 protective orders, § 4:65 to 4:68
 regulatory bars, § 4:67
 same biological product, § 4:63
 Newly issued or licensed patents,
 § 4:21
**Notice of Commercial Market-
 ing (NCM)** (this index)
Patent Dance (this index)
Patent Infringement Liability
 (this index)
Post-Grant Proceedings (this
 index)
 Preliminary injunctions, § 4:58,
 4:64
Remedies (this index)
 Scheduling and staging, § 4:59,
 4:60

CITIZEN PETITIONS

FDA approval process, § 3:22

COMMENCEMENT OF SUIT

Generally, § 4:32 to 4:57
Declaratory Judgment Action
 (this index)
Jurisdiction (this index)
Jury Trial (this index)
 Limitation on claims
 generally, § 4:51 to 4:54
 failure of applicant to provide
 notice, § 4:52
 first wave litigation, § 4:53
 scope-limiting ability of
 applicant, § 4:53
 second wave litigation, § 4:54
 Standing, § 4:42
Venue (this index)

**CONFIDENTIAL
INFORMATION**

Patent Dance (this index)
 Protective orders, confidentiality
 tiers, § 4:68

CONSTRUCTION

Patent infringement liability, claim
 construction, § 4:70

COUNTERCLAIMS

Reference product sponsor (RPS),
 right to bring declaratory
 judgment action, § 4:49

**DECLARATORY JUDGMENT
ACTION**

Reference product sponsor (RPS),
 right to bring
 262(l)(9)(A), § 4:46
 262(l)(9)(B), § 4:45
 262(l)(9)(C), § 4:44 to 4:46
 generally, § 4:43 to 4:50
 counterclaims, application to,
 § 4:49
 discretionary exercise of
 declaratory judgment juris-
 diction, § 4:50
 limits on ability of applicants to
 seek declaratory relief,
 § 4:47
 non-jurisdictional treatment by
 courts, § 4:48
 timing of suit, § 4:46
 Venue, § 4:37 to 4:39

DISCOVERY

**Biologics Price Competition and
 Innovation Act (BPCIA)**
 (this index)
 Foreign litigation
 generally, § 7:1 to 7:4
 discretion, § 7:4
 ex parte application, § 7:3
 Section 1782 Action, § 7:2 to
 7:4

DOCTRINE OF EQUIVALENTS

Patent infringement liability, direct
 infringement, § 4:76

INDEX

DOUBLE PATENTING

Obviousness-type, § 4:85

ENFORCEMENT AND ENFORCEABILITY

Antitrust Actions (this index)

Intellectual property acquisition
and enforcement. **Antitrust
Actions** (this index)

NCM provisions, § 4:26

Patent dance, confidential infor-
mation, § 4:13

Patent Infringement Liability
(this index)

Remedies (this index)

ENSNAREMENT

Patent infringement liability, direct
infringement, § 4:78

ESTOPPEL

Generally, § 5:13 to 5:16

Patent infringement liability, pros-
ecution history estoppel,
§ 4:77

Patent owner estoppel, § 5:16

Real parties in interest and privity,
§ 5:14

Scope of estoppel, § 5:15

EXCLUSIVITY

FDA approval process, provisions
impacting biosimilars, § 3:17
to 3:20

EX PARTE APPLICATION

Discovery, foreign litigation, § 7:3

FDA APPROVAL

Generally, § 3:1

Application Types (this index)

Process

generally, § 3:16 to 3:23

citizen petitions, § 3:22

complete response letters,
§ 3:23

exclusivity provisions impact-
ing biosimilars, § 3:17 to
3:20

naming, § 3:21

FDA APPROVAL—Cont'd

Process—Cont'd

orphan drug exclusivity, § 3:20

pediatric exclusivity, § 3:19

reference product exclusivity,
§ 3:18

review timeline, § 3:16 to 3:20

FIRST WAVE LITIGATION

Commencement of suit, limitation
on claims, § 4:53

Patent dance, § 4:19, 4:20

FOREIGN MATTERS

Discovery in the US for use in
foreign litigation. **Discovery**
(this index)

**International Trade Commission
(ITC)** (this index)

Patent infringement liability,
products manufactured
abroad using domestically
patented process, § 4:75

Venue, foreign defendants, § 4:36

FRAUD

Antitrust actions, intellectual prop-
erty acquisition and enforce-
ment, walker process, § 8:4

INJUNCTIONS

Permanent injunctive relief, § 4:97

Preliminary Injunctions (this
index)

INSPECTIONS

Post-licensure requirements,
establishment inspection,
§ 3:24

INTERCHANGEABILITY

Abbreviated biologics license
applications (aBLAs), § 3:11,
3:12

INTERNATIONAL TRADE COMMISSION (ITC)

Comparison between Section 337
investigations and district
court litigations, § 6:4

**INTERNATIONAL TRADE
COMMISSION (ITC)**

—Cont'd

Elements of Section 337 violation,
§ 6:2

Remedies, § 6:3

Section 337 actions, § 6:1 to 6:4

JOINDER

Post-grant proceedings, § 5:18

JURISDICTION

Discretionary exercise of declara-
tory judgment jurisdiction,
§ 4:50

Personal, § 4:41

Product liability claims, primary
jurisdiction, § 9:5

Subject matter, § 4:40

JURY TRIAL

Generally, § 4:55 to 4:57

Biosimilar v. biosimilar patent
cases, § 4:57

BPCIA cases, § 4:56

Right to, § 4:55 to 4:57

LABELING

Product liability claims, FDA
biosimilar labeling, § 9:2

MANUFACTURING

Abbreviated biologics license
applications (aBLAs),
manufacturing information,
§ 3:7

BPCIA, discovery, manufacturing
information, § 4:62

Product liability claims,
manufacturing defect claims,
§ 9:3

MOTIONS

Stay, § 5:12

NAMES AND NAMING

FDA approval process, § 3:21

NEGOTIATION

Patent dance, § 4:19, 4:20

**NOTICE OF COMMERCIAL
MARKETING (NCM)**

Generally, § 4:22 to 4:31

Second wave litigation

generally, § 4:28 to 4:31

appearance of, § 4:31

factors impacting bringing suit
after NCM provided,
§ 4:30

who can bring suit after
applicant provides NCM,
§ 4:29

Statute governing NCM

generally, § 4:23 to 4:27

enforcement of NCM provi-
sions, § 4:26

requirements for providing
NCM, § 4:25

timing of NCM, § 4:24

Timing of NCM, § 4:24

OBVIOUSNESS

Double patenting, obviousness-
type, § 4:85

Ineligible subject matter, § 4:83

Validity, § 4:83, 4:85

ORPHAN DRUGS

FDA approval process, orphan
drug exclusivity, § 3:20

PATENT DANCE

3A statement, § 4:14

3B statement by biosimilar
applicant

generally, § 4:15 to 4:17

detailed statement, § 4:17

list, § 4:16

3C statement by RPS, § 4:18

Generally, § 4:2 to 4:20

Confidential information, protec-
tion

generally, § 4:8 to 4:13

enforceability, § 4:13

prosecution bar, § 4:10

recipients of confidential infor-
mation, § 4:9 to 4:11

regulatory bar, § 4:11

INDEX

PATENT DANCE—Cont'd

- Confidential information, protection—Cont'd
 - use during and after patent dance, § 4:12
- Disclosure of product information to RPS
 - generally, § 4:3 to 4:7
 - additional requested information, § 4:7
 - consequences of failure to provide, § 4:6
 - copy of aBLA, § 4:4
 - “such other information,” § 4:5
- First wave of litigation, § 4:19, 4:20
- Negotiation, § 4:19, 4:20
- Reference product sponsor (RPS)
 - disclosure of product information to RPS, above statements, § 4:14, 4:18
- Unenforceability allegations, § 4:88, 4:89

PATENT INFRINGEMENT LIABILITY

- Generally, § 4:69 to 4:79
- Claim construction, § 4:70
- Direct infringement, literal, § 4:71
- Doctrine of equivalents, § 4:76
- Enforceability
 - generally, § 4:86 to 4:89
 - inequitable conduct, § 4:88
 - unclean hands, § 4:87
 - unenforceability allegations in BPCIA patent dance, § 4:89
- Ensnarement, § 4:78
- Indirect infringement
 - generally, § 4:72 to 4:78
 - contributory infringement, § 4:74
 - doctrine of equivalents, § 4:76
 - ensnarement, § 4:78
 - induced infringement, § 4:73
 - products manufactured abroad using domestically

PATENT INFRINGEMENT

LIABILITY—Cont'd

- Indirect infringement—Cont'd
 - patented process, § 4:75
 - prosecution history estoppel, § 4:77
 - safe harbor, § 4:79
- Literal direct infringement, § 4:71
- Safe harbor, § 4:79
- Validity of patent. **Validity** (this index)

PEDIATRICS

- FDA approval process, pediatric exclusivity, § 3:19

POST-GRANT PROCEEDINGS

- Generally, § 5:1 to 5:20
- Appeals, § 5:20
- Estoppel** (this index)
- Joinder, § 5:18
- Parallel post-grant proceedings and BPCIA litigations, § 5:3
- Serial petitions, § 5:19
- Settlement, § 5:17
- Stays** (this index)

POST-LICENSURE REQUIREMENTS

- Additional requirements, § 3:25
- Establishment inspection, § 3:24
- Promotional labeling and advertising considerations for prescription biological reference, biosimilar and interchangeable biosimilar products, § 3:26

PREEMPTION

- Product liability claims, field preemption, § 9:5

PRELIMINARY INJUNCTIONS

- Generally, § 4:58
- Expedited discovery, § 4:64

PRODUCT LIABILITY CLAIMS

- Generally, § 9:1 to 9:5
- Failure to warn claims, § 9:1

PRODUCT LIABILITY CLAIMS

—Cont'd

- Field preemption, § 9:5
- Labeling, FDA biosimilar labeling, § 9:2
- Manufacturing defect claims, § 9:3
- Primary jurisdiction, § 9:5
- Product design defect claims, § 9:4

PROTECTIVE ORDERS

- Generally, § 4:65 to 4:68
- Confidentiality tiers, § 4:68
- Prosecution bars, § 4:66
- Regulatory bars, § 4:67

REFERENCE PRODUCTS

- Abbreviated biologics license applications (aBLAs), consequences of comparison, § 3:10
- FDA approval process, reference product exclusivity, § 3:18
- Reference product sponsor (RPS)
 - Declaratory Judgment Action** (this index)
 - Patent Dance** (this index)

REMEDIES

- Generally, § 4:90 to 4:98
- Conforming amendments of BPCIA, § 4:91
- Delaying effective date of FDA approval, § 4:92
- Enforceability of patent
 - at-risk launch, § 4:95
 - attorneys' fees, § 4:96
 - monetary damages, § 4:94, 4:95
 - pre-market activity, § 4:94
 - safe harbor, § 4:94
- Injunctions** (this index)
- ITC remedies, § 6:3
- Limitations on remedies, § 4:98
- Monetary damages, enforceability of patent, § 4:94, 4:95
- Monetary relief, § 4:93 to 4:95

SAFE HARBOR

- Patent infringement liability, § 4:79
- Remedies, enforceability of patent, § 4:94

SECOND WAVE LITIGATION

- Commencement of suit, limitation on claims, § 4:54
- Notice of Commercial Marketing (NCM)** (this index)

SERIAL PETITIONS

- Post-grant proceedings, § 5:19

SETTLEMENT

- Antitrust actions, challenges to patent settlement agreements, § 8:2
- Post-grant proceedings, § 5:17

STANDING

- Commencement of suit, § 4:42

STAYS

- Generally, § 5:4 to 5:11
- Motions to stay, § 5:12
- Simplification of issues, § 5:6
- Stage of litigation, § 5:5
- Undue prejudice
 - generally, § 5:7 to 5:11
 - relationship of parties, § 5:11
 - review request, timing, § 5:8
 - status of review proceedings, § 5:10
 - stay request, timing, § 5:9

TIME AND TIMING

- Declaratory judgment action, right of RPS to bring, § 4:46
- FDA approval process, review timeline, § 3:16 to 3:20
- Notice of commercial marketing (NCM), timing of, § 4:24
- Remedies, delaying effective date of FDA approval, § 4:92
- Review request, timing, § 5:8
- Scheduling and staging, § 4:60

INDEX

TIME AND TIMING—Cont'd

Scheduling and staging, BPCIA,
§ 4:59

Stay request, timing, § 5:9

TRIALS

Biologics license applications
(BLAs), abbreviated applica-
tions, § 3:8

UNCLEAN HANDS

Patent infringement liability,
enforceability, § 4:87

VALIDITY

Generally, § 4:80 to 4:85

Enablement, lack of, § 4:84

Indefiniteness, § 4:84

Ineligible subject matter
generally, § 4:81 to 4:83
anticipation, § 4:82
obviousness, § 4:83

VALIDITY—Cont'd

Obviousness-type double patent-
ing, § 4:85

Written description, lack of,
§ 4:84

VENUE

Generally, § 4:32 to 4:39

Declaratory judgment, § 4:37 to
4:39

Patent infringement actions
generally, § 4:33 to 4:36
declaratory judgment, § 4:38,
4:39

defendant's residence, § 4:34

foreign defendants, § 4:36

infringement, § 4:35

place of business, § 4:35

WRITTEN DESCRIPTION

Validity, lack of written descrip-
tion, § 4:84